Preliminary phase II study results of BBR2778 in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.

被引：0
|
作者：
Herbrecht, R
Borchmann, P
Wilhelm, M
Morschhauser, F
Hess, G
Kutz, K
Comis, S
Laffranchi, BL
Engert, A
机构：
[1] Hop Hautepierre, Dept Hematol & Oncol, Strasbourg, France
[2] Univ Cologne, Innere Med Klin 1, Cologne, Germany
[3] Klinikum Nurnberg N, Med Klin, Nurnberg, Germany
[4] Hop Huriez, Serv Pr Bauters, Lille, France
[5] Univ Mainz, Med Klin & Poliklin 3, D-6500 Mainz, Germany
[6] Accelpharm, Basel, Switzerland
[7] Cell Therapeut Inc, Clin Dept, Milan, Italy
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2489
引用
收藏
页码：682A / 683A
页数：2
相关论文
共 50 条
  • [41] Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, novantrone (mitoxantrone), vincristine, prednisone (TNOP)
    Lichtman, SM
    Kolitz, J
    Budman, DR
    Schulman, P
    Vinciguerra, V
    Hoffman, M
    Mittelman, A
    Allen, SL
    Fusco, D
    Hayes, FA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (04): : 360 - 362
  • [42] Phase II study of oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma: Final results.
    Oki, Y
    McLauhlin, P
    Pro, B
    Hagemeister, FH
    Bleyer, A
    Loyer, E
    Younes, A
    BLOOD, 2004, 104 (11) : 684A - 684A
  • [43] Paclitaxel and topotecan in combination with rituximab as effective salvage regimen in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Canales, MA
    Sanjurjo, MJ
    Garcia-Vela, JA
    de Paz, R
    Gracia, J
    Hernandez, D
    Bustos, JG
    Hernandez-Navarro, F
    BLOOD, 2003, 102 (11) : 289B - 289B
  • [44] Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255
    Lichtman, SM
    Niedzwiecki, D
    Barcos, M
    Carlisle, TL
    Cooper, MR
    Johnson, JL
    Peterson, BA
    ANNALS OF ONCOLOGY, 2000, 11 (09) : 1141 - 1146
  • [45] Phase II trial of Doxil® in patients with refractory/relapsed low-grade non-Hodgkin's lymphoma.
    Di Bella, NJ
    Khan, MM
    Dakhil, SR
    Logie, KW
    Marsland, TA
    Simon, SR
    Weinstein, RE
    BLOOD, 2000, 96 (11) : 236B - 236B
  • [46] A phase II trial of Rituximab plus ESHAP as salvage chemotherapy in relapsed/refractory aggressive histology non-Hodgkin's lymphoma.
    Piliotis, EG
    Mangel, J
    Buckstein, R
    Imrie, K
    Spaner, D
    Reis, M
    Foden, C
    Boudreau, A
    Richardson, P
    Richardson, J
    Berinstein, N
    BLOOD, 2003, 102 (11) : 288B - 288B
  • [47] Phase II study of Paclitaxel plus Topotecan with G-CSF support for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Younes, A
    Okpara, N
    Romaguera, JE
    Hagemeister, FB
    McLaughlin, P
    Rahman, D
    Cabanillas, F
    BLOOD, 1999, 94 (10) : 270B - 270B
  • [48] Phase II study of paclitaxel plus topotecan with G-CSF support for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Younes, A
    Rahman, D
    Hagemeister, F
    Romaguera, J
    McLaughlin, P
    Cabanillas, F
    BLOOD, 1998, 92 (10) : 621A - 621A
  • [49] Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin's lymphoma: A phase II study
    Macpherson, N.
    Belch, A.
    Taylor, M.
    Sutherland, J.
    Czaykowski, P.
    Connors, J.
    LEUKEMIA & LYMPHOMA, 2006, 47 (07) : 1327 - 1332
  • [50] Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
    Vose, JM
    Link, BK
    Grossbard, ML
    Czuczman, M
    Grillo-Lopez, A
    Gilman, P
    Lowe, A
    Kunkel, LA
    Fisher, RI
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 389 - 397
12345